Atossa Therapeutics, Inc. (ATOS)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Atossa Therapeutics, Inc. has not issued a press release in this window.
SEC filings
All filings →Atossa Therapeutics, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Atossa Therapeutics, Inc. has no reported insider trades in the last 90 days.